EUVIMEDObjevte EUVIMED
Open access

TET2 mutations were predictive of inferior prognosis in the presence of ASXL1 mutations in patients with chronic myelomonocytic leukemia

Yajuan Cui, Hongyan Tong, Xin Du, Bing Li, Robert Peter Gale, Tiejun Qin, Jinqin Liu, Zefeng Xu, Yue Zhang, Gang Huang, Jie Jin, Liwei Fang and 5 more

Stem Cell Investigation · 2016-09-26 · 3 · 50-50

DOI: 10.21037/sci.2016.09.04 ↗

At a glance

Journal article in Stem Cell Investigation, published online on 2016-09-26. Written by Yajuan Cui and 16 co-authors. Institution: MDS and MPN Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin …. Cited 13 times so far (Crossref). The full text is freely available in PubMed Central.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

BACKGROUND: Somatic mutations involving epigenetic regulators, histone modification and chromatin regulation, splicing components, transcription factors and signaling regulator genes are common in chronic myelomonocytic leukemia (CMML) patients. It has been consensus that ASXL1 mutations have adversely impact on overall survival (OS), while the effect of TET2 mutations remains controversial and undefined. METHODS: ASXL1 and TET2 mutations were analyzed in 141 patients with CMML using Sanger sequencing, with the aim to identify the interplay of ASXL1 and TET2 mutations in the prognosis of CMML. RESULTS: Sixty-five (46.1%) of the CMML patients harbored ASXL1 mutations (frameshift and nonsense), and 46 (32.6%) had TET2 mutations (frame shift, nonsense and missense). In a separate multivariable analysis that included the Mayo Prognostic Model as a single variable along with ASXL1wt/TET2wt, the respective hazard ratios of ASXL1mut/TET2mut, ASXL1mut/TET2wt and ASXL1wt/TET2mut were 4.7 (95% CI, 2.2-10.3; P

Subjects

Author keywords

ASXL1 mutationsTET2 mutationschronic myelomonocytic leukemia (CMML)prognosis

Authors and institutions

  • MDS and MPN Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China;; State Key Laboratory of Experimental Hematology, Insti…
  • Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou 310000, China.
  • Department of Hematology, Guangdong General Hospital, Guangzhou 510010, China.
  • Hematology Research Center, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, UK.
  • MDS and MPN Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.
  • State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.

Cite

APA

Cui, Y., Tong, H., Du, X., Li, B., Gale, R. P., Qin, T., Liu, J., Xu, Z., Zhang, Y., Huang, G., Jin, J., Fang, L., Zhang, H., Pan, L., Hu, N., Qu, S., & Xiao, Z. (2016). TET2 mutations were predictive of inferior prognosis in the presence of ASXL1 mutations in patients with chronic myelomonocytic leukemia. Stem Cell Investigation, 3, 50-50. https://doi.org/10.21037/sci.2016.09.04

Vancouver

Cui Y, Tong H, Du X, Li B, Gale RP, Qin T, et al. TET2 mutations were predictive of inferior prognosis in the presence of ASXL1 mutations in patients with chronic myelomonocytic leukemia. Stem Cell Investigation. 2016;3:50-50. doi:10.21037/sci.2016.09.04

BibTeX
@article{Cui2016,
  author = {Cui, Yajuan and Tong, Hongyan and Du, Xin and Li, Bing and Gale, Robert Peter and Qin, Tiejun and Liu, Jinqin and Xu, Zefeng and Zhang, Yue and Huang, Gang and Jin, Jie and Fang, Liwei and Zhang, Hongli and Pan, Lijuan and Hu, Naibo and Qu, Shiqiang and Xiao, Zhijian},
  title = {TET2 mutations were predictive of inferior prognosis in the presence of ASXL1 mutations in patients with chronic myelomonocytic leukemia},
  journal = {Stem Cell Investigation},
  year = {2016},
  volume = {3},
  pages = {50--50},
  doi = {10.21037/sci.2016.09.04}
}
Start for free →